Screener / SEC EDGAR /CIK 0000887359 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Vericel Corp VCEL

Compare with peers Embed
Planned sales, announced before they happen

7 trading plans running, 36 Form 144 notices for $14.6M

10-Q, 10-K and Form 144
Plans running now 7 Dominick Colangelo, Kevin McLaughlin, Robert Zerbe, Heidi Hagen, Joseph Mara, Michael Halpin
Plans adopted 29 reported since May 10, 2023 Form 144 notices 36 $14.6M the sellers expected to sell

What VCEL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 23, 2025 to Nov 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Dominick Colangelo
Chief Executive Officer
Adopted 10b5-1 plan Aug 25, 2026 10-Q Nov 5, 2026
What the company wrote
On August 25, 2026, Dominick Colangelo, Vericel Corporation’s Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 279,307 shares of our common stock between December 9, 2026 and August 27, 2027. All of the shares subject to this arrangement are in the form of stock options that were awarded to Mr. Colangelo on February 7, 2018, and which would otherwise expire and become forfeitable on February 7, 2028.
Kevin McLaughlin
member of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan Aug 19, 2026 10-Q Nov 5, 2026
What the company wrote
On August 19, 2026, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 26,250 shares of our common stock between February 10, 2027 and November 30, 2027.
Robert Zerbe
Chairman of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan May 19, 2026 10-Q Jul 30, 2026
What the company wrote
On May 19, 2026, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 33,750 shares of our common stock between August 31, 2026 and September 30, 2027.
Jonathan Siegal
Principal Accounting Officer
Adopted 10b5-1 plan Dec 10, 2025 10-K Feb 26, 2026
What the company wrote
On December 10, 2025, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 63,136 shares of our common stock between March 10, 2026 and November 6, 2026.
Heidi Hagen
member of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan Dec 4, 2025 10-K Feb 26, 2026
What the company wrote
On December 4, 2025, Heidi Hagen, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 17,500 shares of our common stock between March 30, 2026, and May 28, 2027; and
Joseph Mara
Chief Financial Officer
Adopted 10b5-1 plan Dec 2, 2025 10-K Feb 26, 2026
What the company wrote
On December 2, 2025, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 160,000 shares of our common stock between March 2, 2026, and March 5, 2027; and
Michael Halpin
Chief Operating Officer
Adopted 10b5-1 plan Dec 2, 2025 10-K Feb 26, 2026
What the company wrote
On December 2, 2025, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 49,575 shares of our common stock between March 2, 2026, and February 26, 2027; and
Sean Flynn
Chief Legal Officer
Adopted 10b5-1 plan Dec 2, 2025 10-K Feb 26, 2026
What the company wrote
On December 2, 2025, Sean Flynn, Vericel Corporation’s Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 71,825 shares of our common stock between March 2, 2026 and November 6, 2026, and terminated a prior Rule 10b5-1 trading arrangement dated March 5, 2025; and
Jonathan Hopper
Chief Medical Officer
Adopted 10b5-1 plan May 30, 2025 10-Q Jul 31, 2025
What the company wrote
On May 30, 2025, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 37,847 shares of our common stock between September 2, 2025 and August 28, 2026.
Robert Zerbe
Chairman of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan May 23, 2025 10-Q Jul 31, 2025
What the company wrote
On May 23, 2025, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 7,500 shares of our common stock between September 2, 2025 and August 28, 2026; and
Kevin McLaughlin
member of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan May 12, 2025 10-Q Jul 31, 2025
What the company wrote
On May 12, 2025, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 35,000 shares of our common stock between November 10, 2025 and November 30, 2026;
Jonathan Siegal
Principal Accounting Officer
Adopted 10b5-1 plan Mar 14, 2025 10-Q May 8, 2025
What the company wrote
On March 14, 2025, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 51,798 shares of our common stock between June 12, 2025 and February 27, 2026.
Sean Flynn
Chief Legal Officer
Adopted 10b5-1 plan Mar 5, 2025 10-Q May 8, 2025
What the company wrote
On March 5, 2025, Sean Flynn, Vericel Corporation’s Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 41,825 shares of our common stock between June 5, 2025 and June 30, 2026; and
Dominick Colangelo
President and Chief Executive Officer
Adopted 10b5-1 plan Dec 2, 2024 10-K Feb 27, 2025
What the company wrote
On December 2, 2024, Dominick Colangelo, Vericel Corporation’s President and Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 131,008 shares of our common stock between March 12, 2025, and June 2, 2025.
Michael Halpin
Chief Operating Officer
Adopted 10b5-1 plan Nov 19, 2024 10-K Feb 27, 2025
What the company wrote
On November 19, 2024, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 30,000 shares of our common stock between March 3, 2025, and February 27, 2026.
Joseph Mara
Chief Financial Officer
Adopted 10b5-1 plan Nov 15, 2024 10-K Feb 27, 2025
What the company wrote
On November 15, 2024, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement. Mr. Mara subsequently amended that trading arrangement on November 26, 2024. The amended trading arrangement provides for the potential sale of up to 88,500 shares of our common stock between March 3, 2025, and December 31, 2025.
Heidi Hagen
member of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan Nov 14, 2024 10-K Feb 27, 2025
What the company wrote
On November 14, 2024, Heidi Hagen, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 24,000 shares of our common stock between March 3, 2025, and March 27, 2026.
Steven Gilman
member of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan May 30, 2024 10-Q Aug 1, 2024
What the company wrote
On May 30, 2024, Steven Gilman, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 22,500 shares of our common stock between September 4, 2024, and April 30, 2025.
Jonathan Hopper
Chief Medical Officer
Adopted 10b5-1 plan May 28, 2024 10-Q Aug 1, 2024
What the company wrote
On May 28, 2024, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 40,000 shares of our common stock between September 3, 2024 and August 29, 2025.
Joseph Mara
Chief Financial Officer
Adopted 10b5-1 plan Mar 15, 2024 10-Q May 8, 2024
What the company wrote
On March 15, 2024, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 5,000 shares of our common stock between June 13, 2024 and May 30, 2025.
Jonathan Siegal
Principal Accounting Officer
Adopted 10b5-1 plan Mar 13, 2024 10-Q May 8, 2024
What the company wrote
On March 13, 2024, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 42,577 shares of our common stock between June 13, 2024 and February 28, 2025; and
Sean Flynn
Chief Legal Officer
Adopted 10b5-1 plan Mar 13, 2024 10-Q May 8, 2024
What the company wrote
On March 13, 2024, Sean Flynn, Vericel Corporation’s Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 40,075 shares of our common stock between June 13, 2024 and May 30, 2025;
Robert Zerbe
Chairman of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan Mar 12, 2024 10-Q May 8, 2024
What the company wrote
On March 12, 2024, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 17,500 shares of our common stock between September 3, 2024, and August 29, 2025;
Kevin McLaughlin
member of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan Mar 11, 2024 10-Q May 8, 2024
What the company wrote
On March 11, 2024, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 35,000 shares of our common stock between August 7, 2024, and August 8, 2025;
Jonathan Siegal
Principal Accounting Officer
Adopted 10b5-1 plan Sep 14, 2023 10-Q Nov 8, 2023
What the company wrote
On September 14, 2023, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 23,800 shares of our common stock between December 13, 2023 and May 17, 2024.
Dominick Colangelo
President and Chief Executive Officer
Adopted 10b5-1 plan Sep 1, 2023 10-Q Nov 8, 2023
What the company wrote
On September 1, 2023, Dominick Colangelo, Vericel Corporation’s President and Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 431,849 shares of our common stock between December 6, 2023 and December 31, 2024; and
Michael Halpin
Chief Operating Officer
Adopted 10b5-1 plan Aug 31, 2023 10-Q Nov 8, 2023
What the company wrote
On August 31, 2023, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 32,834 shares of our common stock between November 30, 2023 and August 30, 2024;
Jonathan Hopper
Chief Medical Officer
Adopted 10b5-1 plan Aug 17, 2023 10-Q Nov 8, 2023
What the company wrote
On August 17, 2023, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 15,000 shares of our common stock between November 20, 2023 and October 31, 2024;
Robert Zerbe
Chairman of the Vericel Corporation Board of Directors
Adopted 10b5-1 plan Aug 11, 2023 10-Q Nov 8, 2023
What the company wrote
On August 11, 2023, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 17,000 shares of our common stock between November 15, 2023, and August 30, 2024;
Show the other 21 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 10, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 13, 2026 SIEGAL JONATHAN
Officer
1,885 $109K
Nov 12, 2026 Mara Joseph Anthony Jr
Officer
8 $478
Nov 10, 2026 MCLAUGHLIN KEVIN F
Director
7,000 $409K
Nov 9, 2026 ZERBE ROBERT L MD
Director
2,000 $116K
Nov 9, 2026 Mara Joseph Anthony Jr
Officer
25,000 $1.5M
Nov 6, 2026 Mara Joseph Anthony Jr
Officer
28,641 $1.5M
Nov 6, 2026 Mara Joseph Anthony Jr
Officer
28,641 $1.5M
Nov 5, 2026 Mara Joseph Anthony Jr
Officer
21,359 $1.1M
Nov 5, 2026 Flynn Sean C.
Officer
15,000 $779K
Nov 5, 2026 ZERBE ROBERT L MD
Director
3,000 $157K
Nov 5, 2026 SIEGAL JONATHAN
Officer
1,500 $79K
Nov 4, 2026 ZERBE ROBERT L MD
Director
2,500 $114K
Aug 12, 2026 MCLAUGHLIN KEVIN F
Director
7,000 $309K
Aug 3, 2026 Halpin Michael
Officer
10,000 $460K
Jul 30, 2026 SIEGAL JONATHAN
Officer
4,500 $220K
Jun 26, 2026 Flynn Sean C.
Officer
15,000 $685K
Jun 26, 2026 Mara Joseph Anthony Jr
Officer
5,000 $224K
Jun 26, 2026 SIEGAL JONATHAN
Officer
2,732 $123K
Jun 26, 2026 Hopper Jonathan Mark
Officer
10,000 $450K
Jun 18, 2026 Flynn Sean C.
Officer
15,000 $603K
Jun 18, 2026 Halpin Michael
Officer
10,000 $402K
Jun 2, 2026 Hopper Jonathan Mark
Officer
4,375 $153K
May 13, 2026 MCLAUGHLIN KEVIN F
Director
7,000 $228K
May 11, 2026 Wotton Paul K
Director
10,000 $327K
May 7, 2026 SIEGAL JONATHAN
Officer
1,422 $58K
May 7, 2026 Mara Joseph Anthony Jr
Officer
5,000 $202K
May 6, 2026 SIEGAL JONATHAN
Officer
3,433 $130K
Apr 2, 2026 Hopper Jonathan Mark
Officer
3,472 $122K
Mar 23, 2026 Hagen Heidi
Director
15,000 $486K
Mar 2, 2026 Flynn Sean C.
Officer
21,421 $754K
Mar 2, 2026 Halpin Michael
Officer
10,305 $364K
Feb 11, 2026 MCLAUGHLIN KEVIN F
Director
7,000 $249K
Jan 7, 2026 Halpin Michael
Officer
10,000 $405K
Dec 3, 2025 Wotton Paul K
Director
2,500 $95K
Dec 2, 2025 Hopper Jonathan Mark
Officer
1,652 $65K
Dec 2, 2025 Wotton Paul K
Director
2,500 $95K
Show the other 28 notices

From the Form 144 XML filed with the SEC, since Dec 2, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.